News and Trends 27 Apr 2017 Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into the mechanism of action of antagonists of the protease-activated receptor 2 (PAR2), a molecule involved in metabolism and inflammatory responses. The study is part of […] April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 How is Biotech Transforming Pharma’s R&D Model? Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances and acquisitions play in this new model? For almost two centuries, medicinal products have brought continuous therapeutic progress. This path is marked by breakthrough innovations, which now allow us to treat diseases previously believed to be incurable. But to bring about […] April 6, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2017 Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635 that reverses adenosine-mediated T cell suppression and enhances anti-tumor immunity. The British company will now receive an €11M ($12M) milestone payment from AstraZeneca, who obtained exclusive global rights […] April 5, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2017 You Can Now Search Worldwide Genomic Data in a Single Platform Access to data is still the main bottleneck for genomic researchers. Repositive has created a free online platform to solve this problem once and for all. Repositive is building an online platform that makes genomic data from different sources easily searchable and accessible from a single portal. Its mission is to speed up genetic diagnostics […] March 27, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2017 Can this British Biotech Overcome Failure buying drugs from AstraZeneca? After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to acquire rights from two AstraZeneca products for pulmonary disease. Circassia could not beat the placebo in a Phase III trial for cat allergy last year, which immediately drove its stock down by 65% and led to the halt of clinical […] March 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2017 UK’s Joint Venture Bridging Academia and Industry is Ready for Kick Off Apollo Therapeutics is a UK-based joint venture bridging academia and industry to drive the translation of university research. Its first four drug discovery programmes will now be launched. Apollo Therapeutics was founded in early 2016 as a collaborative effort of the three global pharmaceutical companies, AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation, and the world-leading UK-universities, Imperial College London, UCL and the University of […] February 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2017 Top 5 Biologicals from European Biopharma to Launch in 2017 A new report listing the top drug launches this year reveals the strong performance of biologicals and European biopharma on the drug market. After the worst year in biotech finance, experts seem to agree that the industry will start recovering in 2017. There are still substantial uncertainties, mostly regarding the new US administration. Though a […] January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jan 2017 The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge Cambridge’s image is tied to its Hogwarts-like University and Nobel-hoarding academia, but there’s also an exciting entrepreneurial scene at the cutting edge of technology. We took a look at how big biotech is in the Silicon Fen. Cambridge’s Biotech cluster has an exemplary hive of talent, infrastructure, and capital – enough to create the same vibe […] January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jan 2017 An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics The MultipleMS Consortium has been granted €15M by the EU Horizon 2020 to improve the treatment of multiple sclerosis using personalized medicine. The EU Horizon 2020 has kicked off the year with a project to develop, validate, and exploit methods for the personalized treatment of multiple sclerosis (MS). The 21 institutions from 12 European countries and […] January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia? Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Amryt has taken out a loan from the European Investment Bank to fund […] December 9, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2016 Stories We Didn’t Cover: MDMA in Phase III, Another Death for Carmat Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Sanofi has acquired Warp Drive Bio’s antibiotics program, which was born out of […] December 2, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2016 Better than ADCs? AstraZeneca bids for Bicyclic Peptides AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Bicycle Therapeutics is a company in Cambridge founded by one of the top biotech leaders in the UK’s golden triangle. Its unique technology […] December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email